ATE243504T1 - Cefadroxilmonohydrat tablettenformulierung - Google Patents

Cefadroxilmonohydrat tablettenformulierung

Info

Publication number
ATE243504T1
ATE243504T1 AT98911832T AT98911832T ATE243504T1 AT E243504 T1 ATE243504 T1 AT E243504T1 AT 98911832 T AT98911832 T AT 98911832T AT 98911832 T AT98911832 T AT 98911832T AT E243504 T1 ATE243504 T1 AT E243504T1
Authority
AT
Austria
Prior art keywords
tablet formulation
cefadroxil monohydrate
monohydrate tablet
cefadroxil
swallowing
Prior art date
Application number
AT98911832T
Other languages
English (en)
Inventor
Jean Paul Louis Auguste Remon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE243504T1 publication Critical patent/ATE243504T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
AT98911832T 1997-04-17 1998-03-19 Cefadroxilmonohydrat tablettenformulierung ATE243504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4414097P 1997-04-17 1997-04-17
PCT/US1998/005412 WO1998046213A1 (en) 1997-04-17 1998-03-19 Cefadroxil monohydrate tablet formulation

Publications (1)

Publication Number Publication Date
ATE243504T1 true ATE243504T1 (de) 2003-07-15

Family

ID=21930720

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98911832T ATE243504T1 (de) 1997-04-17 1998-03-19 Cefadroxilmonohydrat tablettenformulierung

Country Status (11)

Country Link
US (1) US6080427A (de)
EP (1) EP1007006B1 (de)
JP (1) JP2002514212A (de)
AT (1) ATE243504T1 (de)
AU (1) AU729437B2 (de)
CA (1) CA2286079A1 (de)
DE (1) DE69815856T2 (de)
DK (1) DK1007006T3 (de)
ES (1) ES2201465T3 (de)
PT (1) PT1007006E (de)
WO (1) WO1998046213A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814679B1 (fr) * 2000-09-29 2003-04-11 Cll Pharma Compositions pharmaceutiques dispersibles a base de cephalosporines, leur procede de preparation et leur utilisation
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
EP1293251A1 (de) * 2001-09-14 2003-03-19 Holland Sweetener Company V.o.F. Verfahren zur Herstellung von alpha-L-aspartyl-l-phenylalanine methyl ester Pulver
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
JP4743684B2 (ja) * 2002-05-22 2011-08-10 塩野義製薬株式会社 難水溶性薬物の溶出性を改善する方法
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
WO2004016250A1 (en) * 2002-08-19 2004-02-26 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
DE60324944D1 (de) * 2002-08-16 2009-01-08 Orchid Chemicals & Pharm Ltd Pharmazeutische zusammensetzung mit verzögerte freisetzung enthaltend einen cephalosporin-antibiotikum
CN1311830C (zh) * 2004-02-27 2007-04-25 石药集团中奇制药技术（石家庄）有限公司 头孢羟氨苄口腔崩解片及其制备方法
MXPA06012944A (es) * 2004-05-10 2007-02-12 Lupin Ltd Nueva formulaci??n farmaceutica de cefixima con mejor biodisponibilidad.
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
BRPI0620578A2 (pt) * 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
WO2008104996A2 (en) * 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN104800177B (zh) * 2015-05-12 2018-01-16 湖南科伦制药有限公司 一种头孢羟氨苄片及其制备方法
WO2018143423A1 (ja) * 2017-02-03 2018-08-09 株式会社東洋新薬 固形製剤
CN111388432A (zh) * 2020-03-19 2020-07-10 潍坊富邦药业有限公司 一种宠物用头孢羟氨苄片及其制备方法
CN113908134B (zh) * 2021-12-03 2023-10-27 陕西恒诚制药有限公司 一种头孢羟氨苄分散包衣片的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3584114A (en) * 1968-05-22 1971-06-08 Hoffmann La Roche Free-flowing powders
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3873694A (en) * 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
EP0181966A1 (de) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Pressdragierte dispergierbare Tabletten
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
US5256440A (en) * 1992-06-22 1993-10-26 Merck & Co., Inc. Process for producing a tablet core aperture
ES2175073T3 (es) * 1995-02-08 2002-11-16 Yamanouchi Europ Bv Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.

Also Published As

Publication number Publication date
DK1007006T3 (da) 2003-09-29
WO1998046213A1 (en) 1998-10-22
AU6569798A (en) 1998-11-11
EP1007006B1 (de) 2003-06-25
ES2201465T3 (es) 2004-03-16
DE69815856T2 (de) 2004-05-06
US6080427A (en) 2000-06-27
EP1007006A1 (de) 2000-06-14
AU729437B2 (en) 2001-02-01
PT1007006E (pt) 2003-10-31
JP2002514212A (ja) 2002-05-14
DE69815856D1 (de) 2003-07-31
EP1007006A4 (de) 2001-08-16
CA2286079A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
ATE243504T1 (de) Cefadroxilmonohydrat tablettenformulierung
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
DE59802670D1 (de) Osmotisches arzneimittelfreisetzungssystem
BR9912979B1 (pt) composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
HK1076605A1 (en) Formulations
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
GB9808796D0 (en) Antithrombotic agents
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
WO2005007137A8 (de) Ambroxolhaltige tabletten
EA199900102A1 (ru) Таблетка малеата тримебутина, покрытая оболочкой
MY137516A (en) Pharmaceutical composition comprising lumiracoxib
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
HUP0001104A2 (hu) Ibuprofent és domperidont tartalmazó készítmények migrén kezelésére
SI1596841T1 (sl) Terapevtski sistem amoksicilina in klavulanske kisline
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
PT1202956E (pt) Derivados terapeuticos e/ou nuricionalmente melhorados de ingredientes activos e composicoes de administracao oral contendo o mesmo
GEP20043377B (en) Pharmaceutical Complex
EP1273301A3 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung bieten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007006

Country of ref document: EP